Modulation of P-Glycoprotein Function by St John’s Wort Extract and its Major Constituents

Introduction: Recent data suggest some relevant drug interactions caused by St John’s wort extract, which can be explained by interactions with the Cytochrome P450 system or P-Glycoprotein (Pgp). Interaction with Pgp, including activation, inhibition and induction, can lead to altered plasma or brain levels of Pgp substrates. The aim of the present study was to investigate the possible interactions of St John’s wort extract and most relevant constituents with the transport activity of Pgp. Methods: We characterized the modulatory potencies in two in vitro assays using calcein-AM, first in VLB cells (a human lymphocytic leukemia cell line expressing Pgp) and second in PBCEC cells (porcine brain capillary endothelial cells). Results: The extract, as well as some of the tested constituents modulate the transport by Pgp in the micromolecular range. Quercetin and hyperforin seem to be most potent. Conclusions: These findings suggest the possibility of drug interactions at the level of the gastro-intestinal absorption of drugs. Plasma levels of the constituents of St John’s wort are very likely too low to interfere with Pgp at the blood-brain-barrier with the possible exception of quercetin.

References

• 1 Audus K L, Borchardt R T. Characterization of an In Vitro Blood-Brain Barrier Model System for Studying Drug Transport and Metabolism.  Phamaceutical Research. 1986;  3 81-87
• 2 Barone G W, Gurley B J, Ketel B L, Lightfoot M L, Abul-Ezz S R. Drug interaction between St. John’s wort and cyclosporine.  Ann Pharmacother. 2000;  34 1013-1016
• 3 Bauer B, Miller D S, Fricker G. Compound profiling for P-glycoprotein at the blood-brain barrier using a microplate screening system.  Pharm Res. 2003;  20 1170-1176
• 4 Beck W T, Mueller T J, Tanzer L R. Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts.  Cancer Res. 1979;  39(6 Pt 1) 2070-2076
• 5 Bendayan R, Lee G, Bendayan M. Functional expression and localization of P-glycoprotein at the blood brain barrier.  Microsc Res Tech. 2002;  57 365-380
• 6 Biber A, Fischer H, Romer A, Chatterjee S S. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers.  Pharmacopsychiatry. 1998;  31(Suppl 1) 36-43
• 7 Boulton D W, DeVane C L, Liston H L, Markowitz J S. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.  Life Sci. 2002;  71 163-169
• 8 Cordon-Cardo C, O'Brien J P, Casals D, Rittman-Grauer L, Biedler J L, Melamed M R. et al . Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.  Proc Nat Acad Sci USA. 1989;  86 695-698
• 9 Critchfield J W, Welsh C J, Phang J M, Yeh G C. Modulation of adriamycin accumulation and efflux by flavonoids in HCT- 15 colon cells. Activation of P-glycoprotein as a putative mechanism.  Biochem Pharmacol. 1994;  48 1437-1445
• 10 Durr D, Stieger B, Kullak-Ublick G A, Rentsch K M, Steinert H C, Meier P J. et al . St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.  Clin Pharmacol Ther. 2000;  68 598-604
• 11 Feller N, Broxterman H J, Wahrer D C, Pinedo H M. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion.  FEBS Lett. 1995;  368 385-388
• 12 Franke H, Galla H, Beuckmann C T. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro.  Brain Res Brain Res Protoc. 2000;  5 248-256
• 13 Hennessy M, Kelleher D, Spiers J P, Barry M, Kavanagh P, Back D. et al . St John’s Wort increases expression of P-glycoprotein: implications for drug interactions.  Br J Clin Pharmacol. 2002;  53 75-82
• 14 Hollman P CH. Evidence for health benefits of plant phenols: local or systemic effects.  J Sci Food Agric. 2001;  81 842-852
• 15 Huisman M T, Smit J W, Wiltshire H R, Hoetelmans R M, Beijnen J H, Schinkel A H. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.  Mol Pharmacol. 2001;  59 806-813
• 16 Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum).  Clin Pharmacol Ther. 1999;  66 338-345
• 17 Johne A, Schmider J, Brockmoller J, Stadelmann A M, Stormer E, Bauer S. et al . Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John’s wort (Hypericum perforatum).  J Clin Psychopharmacol. 2002;  22 46-54
• 18 Keller J H, Karas M, Muller W E, Volmer D A, Eckert G P, Tawab M A. et al . Determination of hyperforin in mouse brain by high-performance liquid chromatography/tandem mass spectrometry.  Anal Chem. 2003;  75 6084-6088
• 19 Linde K. MCD. St John’s wort for depression (Cochrane Review). The Cochraine Library 2004 (1)
• 20 Mitsunaga Y, Takanaga H, Matsuo H, Naito M, Tsuruo T, Ohtani H. et al . Effect of bioflavonoids on vincristine transport across blood-brain barrier.  Eur J Pharmacol. 2000;  395 193-201
• 21 Muller W E. Current St John's wort research from mode of action to clinical efficacy.  Pharmacol Res. 2003;  47 101-109
• 22 Muller W E, Rolli M, Schafer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity.  Pharmacopsychiatry. 1997;  30(Suppl 2) 102-107
• 23 Ott M ., Bauer B, Cornelius M, Fricker G. Interactions of Hypericum perforatum compounds with P-Glycoprotein at the blood-brain-barrier.  Naunyn-Schmiedebergs Arch Pharmacol. 2003;  367(Suppl 1) 8
• 24 Perloff M D, von Moltke L L, Stormer E, Shader R I, Greenblatt D J. Saint John’s wort: an in vitro analysis of P-glycoprotein induction due to extended exposure.  Br J Pharmacol. 2001;  134 1601-1608
• 25 Piscitelli S C, Burstein A H, Chaitt D, Alfaro R M, Falloon J. Indinavir concentrations and St John’s wort.  Lancet. 2000;  355(9203) 547-548
• 26 Scambia G, Ranelletti F O, Panici P B, De Vincenzo R, Bonanno G, Ferrandina G. et al . Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target.  Cancer Chemother Pharmacol. 1994;  34 459-64
• 27 Schinkel A H. The physiological function of drug-transporting P-glycoproteins.  Semin Cancer Biol. 1997;  8 161-170
• 28 Schinkel A H. Pharmacological insights from P-glycoprotein knockout mice.  Int J Clin Pharmacol Ther. 1998;  36 9-13
• 29 Schinkel A H, Wagenaar E, Mol C A, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.  J Clin Invest. 1996;  97 2517-2524
• 30 Shapiro A B, Ling V. Effect of quercetin on Hoechst 33 342 transport by purified and reconstituted P-glycoprotein.  Biochem Pharmacol. 1997;  53 587-596
• 31 Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.  Anticancer Drugs. 1996;  7 568-578
• 32 Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption.  Neuropsychopharmacology. 2000;  22 380-387
• 33 Wang Z, Hamman M A, Huang S M, Lesko L J, Hall S D. Effect of St John’s wort on the pharmacokinetics of fexofenadine.  Clin Pharmacol Ther. 2002;  71 414-420
• 34 Weiss J, Dormann S M, Martin-Facklam M, Kerpen C J, Ketabi-Kiyanvash N, Haefeli W E. Inhibition of P-glycoprotein by newer antidepressants.  J Pharmacol Exp Ther. 2003;  305 197-204
• 35 Wonnemann M, Singer A, Siebert B, Muller W E. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John’s wort.  Pharmacopsychiatry. 2001;  34(Suppl 1) S148-151